Kala gets $23M to pay for drug trials in fast-growing eye disease market

With a new $23 million investment and plans to start four mid- to late-stage clinical trials in the next eight months, Kala Pharmaceuticals CEO Guillaume Pfefer said his company is moving “very, very fast...